Research programme: DMT1 inhibitors - Xenon Pharmaceuticals

Drug Profile

Research programme: DMT1 inhibitors - Xenon Pharmaceuticals

Alternative Names: Iron 1; XEN600; XEN600 series

Latest Information Update: 02 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action SLC11A2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Iron overload

Most Recent Events

  • 02 Jun 2010 Preclinical development is ongoing in Canada
  • 20 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO-2005)
  • 29 Jun 2004 Xenon Genetics is now called Xenon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top